Mov Disord Vol 33, Suppl 2 Archives - Page 56 of 177 - MDS Abstracts

2018 International Congress
Neuromelanin sensitive MRI of substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease
L. Jin, J. Wang, Y. Li, Z. Huang, F. Ye (Shanghai, China)
Objective: We aimed to evaluate whether neuromelanin sensitive MRI (NM-MRI) features in the substantia nigra pars compacta(SNc) were of diagnostic value to differentiate untreated ET…
2018 International Congress
Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies
P.Y. Chiu (Changhua, Taiwan)
Objective: Efficacy and safety of rivastigmine solution in the treatment of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) is not well studied…
2018 International Congress
An analysis of cortical thickness in early Parkinson’s disease patients with cognitive impairment
M. Mei, K. Nie, Y. Gao, Y. Zhang, L. Wang (Guangzhou, China)
Objective: To explore a possible relation between the changes of cortical thickness and cognitive deficits in patients with Parkinson’s disease (PD). Background: Cognitive impariment usually…
2018 International Congress
An investigation of the relationship between computational neuropsychological testing outcomes and symptoms of Parkinson’s disease
L. Jiang, Y. Zhu, Z. Ye, Z. Pei, L. Chen (Guangzhou, China)
Objective: The aim of this study was to investigate the relationship between cognition and other symptoms of Parkinson’s disease (PD) using computational neuropsychological tests. Background:…
2018 International Congress
Alzheimer’s Disease Genetic Risk Variants Predict Cognitive Decline in Parkinson’s Disease
T. Tropea, K. Maddy, J. Rick, J. Trojanowkski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)
Objective: To evaluate the effect of genetic variants implicated in Alzheimer’s disease (AD) risk on cognitive decline in Parkinson’s disease (PD). Background: People with PD…
2018 International Congress
Novel GBA risk factor gene mutation p.W378R in a kindred with Gaucher’s disease and Parkinson’s disease
M. Lubomski, M. Hayes, M. Kennerson, M. Ellis, S. Chu, J. Blackie, J. O’Sullivan, G. Nicholson (Sydney, Australia)
Objective: We undertook mutation analysis of the Glucocerebrosidase gene (GBA) gene in a large three-generational Australian kindred consisting of some individuals with both type 1…
2018 International Congress
The Polymorphism of SREBF1 Gene rs11868035 G/A Is Associated with susceptibility to Parkinson’s disease in a Chinese Population
F. Lou, M. Li, XG. Luo, Y. Ren (Shenyang, China)
Objective: The potential association between the single-nucleotide polymorphism of two functional genes (SREBF1gene rs11868035 and USP25 gene rs2823357) and susceptibility to Parkinson’s disease (PD) in…
2018 International Congress
Neuronal KIF5b deletion induces striatum-dependent locomotor impairments and defects in membrane presentation of dopamine D2 receptors
T. Falzone, L. Cromberg, M. Alloatti, I. Fernandez Bessone, T. Saez (Buenos Aires, Argentina)
Objective: In this study we aim to elucidate the role of Kif5b motor subunit in the nigrostriatal pathway. We have generated different conditional knockout mice…
2018 International Congress
Genetic variations of SNCA and striatal dopaminergic dysfunction in patients with Parkinson’s disease
MJ. Lee, K. Pak (Busan, Korea)
Objective: The aim of the present study was to investigate genetic variants in SNCA associated with accelerated deterioration in striatal dopaminergic activity. Background: Widespread a-synuclein…
2018 International Congress
A pilot study of plasma ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) as a potential blood-based biomarker in Parkinson’s disease
A. Ng, YJ. Tan, ZH. Lu, S. Ng, E. Ng, F. Setiawan, N. Keong, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)
Objective: To determine plasma levels of UCH-L1 in patients with PD, and to investigate the association with both genetic (leucine-rich repeat kinase 2, LRRK2 and…